Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
Kim CO, Lee HW, Oh ES, Seong SJ, Kim DY, Lee J, Ahn SH, Yoon YR, Cho CM, Park MS.
Kim CO, et al. Among authors: lee j, lee hw.
J Cardiovasc Pharmacol. 2013 Dec;62(6):524-9. doi: 10.1097/FJC.0000000000000010.
J Cardiovasc Pharmacol. 2013.
PMID: 24084213
Clinical Trial.